Tenofovir alafenamide fumarate therapy in subjects with positive HBV-DNA and normal levels of alanine transaminase: a study protocol for a randomised controlled trial

INTRODUCTION: The current clinical guidelines do not recommend antiviral therapy for subjects with positive hepatitis B virus (HBV)-DNA and normal alanine transaminase (ALT). In this study, we will assess the safety and efficacy of tenofovir alafenamide fumarate (TAF) in the treatment of adults with...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Lu, Wu, Lina, Li, Xuejun, Zhang, Ying, Lai, Jing, Zhu, Xiang, Xie, Chan, Peng, Liang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Gastroenterology and Hepatology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8375735/
https://www.ncbi.nlm.nih.gov/pubmed/34408049
http://dx.doi.org/10.1136/bmjopen-2020-048410

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8375735/
https://www.ncbi.nlm.nih.gov/pubmed/34408049
http://dx.doi.org/10.1136/bmjopen-2020-048410

Ejemplares similares